Share on StockTwits

Shares of Foundation Medicine (NYSE:FMI) have earned an average rating of “Hold” from the nine analysts that are covering the stock, American Banking and Market News reports. Six equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $38.80.

Several analysts have recently commented on the stock. Analysts at Tigress Financial initiated coverage on shares of Foundation Medicine in a research note on Friday, August 1st. They set a “neutral” rating on the stock. Analysts at Janney Montgomery Scott initiated coverage on shares of Foundation Medicine in a research note on Wednesday, June 25th. They set a “neutral” rating and a $28.00 price target on the stock.

Shares of Foundation Medicine (NYSE:FMI) opened at 24.15 on Thursday. Foundation Medicine has a 52-week low of $19.513 and a 52-week high of $45.00. The stock has a 50-day moving average of $25.54 and a 200-day moving average of $28.40. The company’s market cap is $680.8 million.

Foundation Medicine, Inc is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated.

Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.